Adaptimmune Therapeutics (NASDAQ:ADAP) vs. OKYO Pharma (NASDAQ:OKYO) Head to Head Contrast

OKYO Pharma (NASDAQ:OKYO) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Valuation & Earnings

This table compares OKYO Pharma and Adaptimmune Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A
Adaptimmune Therapeutics	$175.04 million	0.86	-$113.87 million	($0.22)	-2.68

OKYO Pharma has higher earnings, but lower revenue than Adaptimmune Therapeutics.

Profitability

This table compares OKYO Pharma and Adaptimmune Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Adaptimmune Therapeutics	-25.43%	-74.15%	-15.09%

Insider and Institutional Ownership

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

OKYO Pharma has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for OKYO Pharma and Adaptimmune Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	0	0	1	0	3.00
Adaptimmune Therapeutics	0	0	4	0	3.00

OKYO Pharma currently has a consensus price target of $7.00, suggesting a potential upside of 503.45%. Adaptimmune Therapeutics has a consensus price target of $2.79, suggesting a potential upside of 372.46%. Given OKYO Pharma’s higher possible upside, equities research analysts plainly believe OKYO Pharma is more favorable than Adaptimmune Therapeutics.

Summary

OKYO Pharma beats Adaptimmune Therapeutics on 6 of the 10 factors compared between the two stocks.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.